Results 61 to 70 of about 32,102 (275)

How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature

Clinical Parkinsonism & Related Disorders, 2023
Introduction: Pretreatment with the antiemetic trimethobenzamide has been recommended practice in the United States (US) to address the risk of nausea and vomiting during initiation of apomorphine treatment.
Stuart H. Isaacson, Richard B. Dewey, Jr., Rajesh Pahwa, Daniel E. Kremens   +3 more
doaj   +1 more source

Antiemetic research: future directions [PDF]

, 2010
PURPOSE AND METHODS: As a part of reviewing the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guidelines in Perugia in 2009, an expert group identified directions for future antiemetic research.
Aapro, Matti, Grunberg, Steven, Herrstedt, Jørn, Molassiotis, Alexander, Morrow, Garry, Olver, Ian   +5 more
core   +1 more source

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

Clinical Hematology International, 2022
Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT.
Sayako Yuda, Shigeo Fuji, Bipin Savani, Katie S. Gatwood   +3 more
doaj   +1 more source

The therapeutic aspects of the endocannabinoid system (ECS) for cancer and their development: from nature to laboratory [PDF]

, 2016
The endocannabinoid system (ECS) is a group of neuromodulatory lipids and their receptors, which are widely distributed in mammalian tissues. ECS regulates various cardiovascular, nervous, and immune system functions inside cells.
Botta, Bruno, Czarnecka, Anna M., Khan, Mohammed I., Król, Magdalena, Sobocińska, Anna A., Szczylik, Cezary   +5 more
core   +1 more source

Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?

Journal of Parkinson’s Disease, 2023
Background: Nausea is common upon initiating dopamine agonists in patients with Parkinson’s disease (PD); however, pretreatment with an antiemetic is recommended only when initiating apomorphine formulations. Objective: Evaluate the need for prophylactic
Robert A. Hauser, William G. Ondo, Yi Zhang, Alyssa Bowling, Bradford Navia, Eric Pappert, Stuart H. Isaacson,   +7 more
doaj   +1 more source

Home death for children dying in six European countries [PDF]

, 2009
Aim: Guidelines on pediatric palliative care underline that care at the end of life of chronically ill children should preferably be provided in the child’s home situation.
Addington-Hall, Julia, Bilsen, Johan, Cohen, Joachim, Deliens, Luc, Kaasa, Stein, Miccinesi, Guido, Mortier, Freddy, Onwuteaka-Philipsen, Bregje, Pousset, Geert   +8 more
core  

Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study [PDF]

, 2017
Nausea is a subjective sensation which is difficult to measure in non-verbal species. The aims of this study were to determine the efficacy of three classes of antiemetic drugs in a novel low dose cisplatin model of nausea and vomiting and measure change
A Freeman, A Tidholm, AM Holmes, B Otto, C Pirri, C Rojas, CC Horn, CC Horn, CJ Henry, DB Smith, DB Zamble, DG Warr, F Roila, F Roila, FD Tattersall, GJ Sanger, GJ Sanger, GR Morrow, H Fukui, H Fukui, H Kenward, H Kenward, Hannah Kenward, JA Gylys, JA Rudd, Jonathan Elliott, K Olsson, Ludovic Pelligand, LX Cubeddu, M Marty, M Mutoh, N Percie du Sert, N Percie du Sert, PH Mulder De, PJ Hesketh, PJ Hesketh, PL Andrews, RJ Gralla, RM Stern, RM Stern, S Kretzing, S Poli-Bigelli, SG Allan, SP Chawla, Terry Lee, TM Hyde, V Napadow, VA Puente-Redondo de la   +47 more
core   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Adherence to guidelines on prophylaxis of chemotherapy-induced nausea and vomiting in the National Cancer Institute, Sudan

South African Journal of Oncology, 2017
Objective: To evaluate the adherence to American Society of Clinical Oncology (ASCO) guidelines for antiemetic prophylaxis of chemotherapy-induced nausea and vomiting and assess the outcomes of the prescribed antiemetic drugs. Methods: This prospective,
Moawia M.A. Elhassan, Arwa A.S.A. Ali, Mohamed O.M. Elmustafa   +2 more
doaj   +1 more source

Targeting tachykinin receptors in neuroblastoma [PDF]

, 2016
Neuroblastoma is the most common extracranial tumor in children. Despite aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge with survival rates below 50%.
Althoff, Kristina, Astrahanseff, Kathy, Beckers, Anneleen, Bergmann, Andreas, De Preter, Katleen, Eggert, Angelika, Henssen, Anton G, Odersky, Andrea, Schramm, Alexander, Schulte, Johannes H, Schäfers, Simon, Seiler, Marleen, Speleman, Franki, Struck, Joachim, Szymansky, Annabell   +14 more
core   +3 more sources